Neurological receptors to evaluate sleep, anxiety, stress, cognitive function, memory using receptor over-expressing cell lines, measuring Agonist/ antagonist activity.

• Cell Model

  Receptor over-expressing cell lines

• End Point

  Agonist/ antagonist activity

• Reference Drugs

  Based on the selected receptor

• Relevance

  Sleep, anxiety, stress, Cognitive function, memory

Biomarker analysis to evaluate sleep, anxiety, stress, Cognitive function, memory using human neuronal cells (SHSY-5Y), measuring modulation of key markers.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Modulation of key markers

• Reference Drugs

  Selegiline

• Relevance

  Sleep, anxiety, stress, Cognitive function, memory

Neurite formation in neuronal cells (PC-12/SHSY- 5Y) to evaluate sleep, anxiety, stress, cognitive function, memory using rat pheochromocytoma cells (PC12), human neuronal cells (SHSY-5Y), measuring neurite outgrowth.

• Cell Model

  Rat Pheochromocytoma cells (PC12), Human Neuronal cells (SHSY-5Y)

• End Point

  Neurite outgrowth

• Reference Drugs

  b-NGF/ Selegiline

• Relevance

  Sleep, anxiety, stress, Cognitive function, memory

Cytoprotection against oxidative stress in neuronal cells (PC-12/SHSY-5Y) in human neuronal cells (SHSY-5Y) to study sleep, anxiety, stress, cognitive function, memory.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Restoration of cell viability

• Reference Drugs

  Selegiline

• Relevance

  Sleep, anxiety, stress, Cognitive function, memory

Apoptosis in neuronal cells (SHSY-5Y) against oxidative stress to evaluate Neuroprotection using Neuronal cells (SHSY-5Y), measuring anti-apoptotic potential against damage.

• Cell Model

  Neuronal cells (SHSY-5Y)

• End Point

  Anti-apoptotic potential against damage

• Reference Drugs

  Selegiline/ Galantamine

• Relevance

  Neuroprotection

Cytokine inhibition in neuronal cells (SHSY-5Y) against oxidative stress to evaluate Neuroprotection using Neuronal cells (SHSY-5Y), measuring inhibition of cytokines as compared to damage.

• Cell Model

  Neuronal cells (SHSY-5Y)

• End Point

  Inhibition of cytokines as compared to damage

• Reference Drugs

  Selegiline/ Galantamine

• Relevance

  Neuroprotection

Cytoprotection against neurotoxin (MPP+) induced damage in neuronal cells (SHSY-5Y) to evaluate Parkinson's disease using Human Neuronal cells (SHSY-5Y), measuring restoration of cell viability.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Restoration of cell viability

• Reference Drugs

  Selegiline

• Relevance

  Parkinson's disease

Antiapoptotic effect against neurotoxin (MPP+) induced damage in neuronal cells (SHSY-5Y) to evaluate Parkinson's disease using human neuronal cells (SHSY-5Y), measuring Annexin, cell cycle, mitochondrial membrane potential.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Annexin, cell cycle, Mitochondrial Membrane Potential

• Reference Drugs

  Selegiline

• Relevance

  Parkinson's disease

Cytokines inhibition against neurotoxin (MPP+) induced damage in neuronal cells (SHSY-5Y) to evaluate Parkinson's disease using Human Neuronal cells (SHSY-5Y), measuring inhibition of cytokines.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Inhibition of Cytokines

• Reference Drugs

  Selegiline

• Relevance

  Parkinson's disease

Neurite formation assay in neuronal cells (PC- 12/SHSY-5Y) to evaluate Parkinson's disease using rat pheochromocytoma cells (PC12), human neuronal cells (SHSY-5Y), measuring neurite outgrowth.

• Cell Model

  Rat Pheochromocytoma cells (PC12), Human Neuronal cells (SHSY-5Y)

• End Point

  Neurite outgrowth

• Reference Drugs

  b-NGF/ Selegiline

• Relevance

  Parkinson's disease

Modulation of Receptors expression to evaluate Parkinson's disease using Receptor over-expressing cell lines, measuring agonist/ antagonist activity.

• Cell Model

  Receptor over-expressing cell lines

• End Point

  Agonist/ antagonist activity

• Reference Drugs

  Based on the selected receptor

• Relevance

  Parkinson's disease

Biomarker analysis by multiplexing to evaluate Parkinson's disease using human neuronal cells (SHSY-5Y), measuring modulation of key markers.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Modulation of key markers

• Reference Drugs

  Selegiline

• Relevance

  Parkinson's disease

Cytoprotection against neurotoxin (Scopolamine) induced damage in neuronal cells (SHSY-5Y) to evaluate Alzheimer's disease using human neuronal cells (SHSY-5Y), measuring restoration of cell viability.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Restoration of cell viability

• Reference Drugs

  Galantamine

• Relevance

  Alzheimer's disease

Antiapoptotic effect against neurotoxin to evaluate Alzheimer's disease using Human Neuronal cells (SHSY-5Y), measuring Annexin, cell cycle, mitochondrial membrane potential.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Annexin, cell cycle, Mitochondrial Membrane Potential

• Reference Drugs

  Galantamine

• Relevance

  Alzheimer's disease

Cytokines inhibition against neurotoxin (Scopolamine) induced damage in neuronal cells (SHSY-5Y) to evaluate Alzheimer's disease using human neuronal cells (SHSY-5Y), measuring inhibition of cytokines.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Inhibition of Cytokines

• Reference Drugs

  Galantamine

• Relevance

  Alzheimer's disease

Neurite formation assay in neuronal cells (PC- 12/SHSY-5Y) to evaluate Alzheimer's disease using rat pheochromocytoma cells (PC12), Human Neuronal cells (SHSY-5Y), measuring neurite outgrowth.

• Cell Model

  Rat Pheochromocytoma cells (PC12), Human Neuronal cells (SHSY-5Y)

• End Point

  Neurite outgrowth

• Reference Drugs

  b-NGF/ Selegiline

• Relevance

  Alzheimer's disease

Modulation of Receptors expression to evaluate Alzheimer's disease using Receptor over-expressing cell lines, measuring agonist/ antagonist activity.

• Cell Model

  Receptor over-expressing cell lines

• End Point

  Agonist/ antagonist activity

• Reference Drugs

  Based on the selected receptor

• Relevance

  Alzheimer's disease

Biomarker analysis by multiplexing to evaluate Alzheimer's disease using human neuronal cells (SHSY-5Y), measuring modulation of key markers.

• Cell Model

  Human Neuronal cells (SHSY-5Y)

• End Point

  Modulation of key markers

• Reference Drugs

  Galantamine

• Relevance

  Alzheimer's disease

Effect on CD markers, MHC in immune cells to evaluate Multiple Sclerosis (MS) using Human Monocytes (THP-1), measuring percentage inhibition in expression against stimulation .

• Cell Model

  Human Monocytes (THP-1)

• End Point

  Percentage inhibition in expression against stimulation

• Reference Drugs

  Dexamethasone

• Relevance

  Multiple Sclerosis (MS)

Cytokine inhibition in glioma cells to evaluate Multiple Sclerosis (MS) using Glioblastoma (U251MG)/ Rat Glial cells(C6), measuring inhibition of cytokines as compared to stimulation .

• Cell Model

  Glioblastoma (U251MG)/ Rat Glial cells(C6)

• End Point

  Inhibition of cytokines as compared to stimulation

• Reference Drugs

  Dexamethasone/ Nicotine

• Relevance

  Multiple Sclerosis (MS)

Biomarker analysis by multiplexing to evaluate Multiple Sclerosis (MS) using Glioblastoma (U251MG)/ Rat Glial cells(C6), measuring modulation of key biomarkers involved.

• Cell Model

  Glioblastoma (U251MG)/ Rat Glial cells(C6)

• End Point

  Modulation of key biomarkers involved

• Reference Drugs

  Dexamethasone/ Nicotine

• Relevance

  Multiple Sclerosis (MS)

Anti-nociceptive activity in CCI-peripheral neuropathy model in rats, measuring pain sensitivity and % activity.

• Animal Model

  Wistar/SD Rats

• End Point

  Pain sensitivity by Pressure application,% Activity

• Reference Drugs

  Gabapentin

Chemotherapy vincristine-induced peripheral neuropathy (CIPN) model in rats, assessing pain sensitivity, % activity, and cytokine estimation.

• Animal Model

  Wistar/SD Rats

• End Point

  Pain sensitivity by Pressure application,% Activity, Cytokine estimation

• Reference Drugs

  Gabapentin

Diabetes-induced neuropathic pain model in rats, evaluating Von-Frey test, tail flick test, and Rota Rod.

• Animal Model

  Wistar/SD Rats

• End Point

  Von- Frey test, Tail Flick test,Rota Rod

• Reference Drugs

  Gabapentin

MPTP-induced Parkinson's model in rats, assessing pole test, traction test, dopamine levels, and brain histology.

• Animal Model

  Wistar/SD Rats

• End Point

  Pole Test,Traction Test, Dopamine level in brain, Brain Histology

• Reference Drugs

  L-DOPA

Anti-dementia activity using scopolamine-induced model in rats or mice, measuring body weight, acetylcholinesterase, and brain histopathology.

• Animal Model

  Wistar, SD Rat/Balb/c Mice

• End Point

  Body weight, Passive Avoidance Test, Acetylcholinesterase, Neural growth factor, TNF-alpha estimation, Histopathology of Brain

• Reference Drugs

  Donepezil Hydrochloride

Anti-dementia activity using STZ (intracerebroventricular) model in rats/mice, assessing Morris Water Maze test, Y Maze, and brain histopathology.

• Animal Model

  Rat/Mice model

• End Point

  Body weight,Morris Water Maze Test, Y Maze, Histopathology of Brain

• Reference Drugs

  Donepezil Hydrochloride

Anti-anxiety activity using elevated plus maze test in rats/mice, measuring time spent in open and closed arms.

• Animal Model

  Wistar, SD Rat & Swiss Albino Mice

• End Point

  Time spent in open & close arm to analyse anxiety

• Reference Drugs

  Diazepam

Anti-depressant activity using forced swim test in rats, evaluating body weight, actimeter, forced swim test, and corticosterone levels.

• Animal Model

  Wistar/SD Rats

• End Point

  Body weight, Feed intake, Actimeter, Force swim Test, Open field Test, Adrenal weight, Corticosterone estimation

• Reference Drugs

  Imipramine

Anti-depressant activity using tail suspension test in rats/mice, assessing body weight, actimeter, and elevated plus maze.

• Animal Model

  Rat & Mice

• End Point

  Body weight, Feed intake, Actimeter, Elevated Plus Maze, Open field Test, Corticosterone estimation

• Reference Drugs

  Imipramine

Muscle relaxant activity using Rota rod test in rats/mice, measuring RPM and time of fall from Rota rod.

• Animal Model

  Wistar, SD Rat & Swiss Albino Mice

• End Point

  RPM-Time of Fall from Rotarod in Sec.

• Reference Drugs

  `--

Learning and memory potential using Morris water maze test in rats, assessing time spent in zones, time to reach hidden platform, and neurotransmitter levels.

• Animal Model

  Wistar/SD Rats

• End Point

  Time spent in NEWS zones, Time to reach hidden platform in water maze (MWM), Acetylcholine, Dopamine level estimation to analyse memory

• Reference Drugs

  `--

Lysolecithin-induced multiple sclerosis model in mice, evaluating pole test, traction test, and brain histology.

• Animal Model

  Balb/c Mice

• End Point

  Pole Test, Traction Test, Brain Histology, IL1 beta

• Reference Drugs

  `--

Anti-stress activity using unpredictable chronic stress (UCS) model in rats, measuring body weight, feed intake, adrenal weight, and corticosterone levels

• Animal Model

  Wistar, SD Rats

• End Point

  Body weight, Feed intake, Actimeter, Elevated Plus Maze, Open field Test, Adrenal weight, Corticosterone, Serotonin, Antioxidant level estimation

• Reference Drugs

  Imipramine

Learning and memory potential using Y-maze test in rats/mice, assessing time spent in center/XYZ zones, acetylcholine and dopamine levels.

• Animal Model

  Rat/Mice

• End Point

  Time spent in Center, XYZ zone, Acetylcholine and Dopamine level, Estimation to analyse Leaning and memory Potential

• Reference Drugs

  `--

MPTP-induced Parkinson's model evaluating motor function through pole and traction tests, dopamine levels in the brain, and brain histology.

• Animal Model

  Mice

• End Point

  Pole Test,Traction Test, Dopamine level in brain, Brain Histology

• Reference Drugs

  L-DOPA

Lysolecithin-induced multiple sclerosis model assessing motor function through pole and traction tests, brain histology, and IL-1 beta levels.

• Animal Model

  Mice

• End Point

  Pole Test, Traction Test, Brain Histology, IL1 beta

• Reference Drugs

  Methylprednisolone

Scopolamine-induced dementia model involves assessing various parameters, including body weight, the Passive Avoidance Test for memory evaluation, acetylcholinesterase activity, neural growth factor levels, TNF-alpha estimation, and histopathological examination of the brain

• Animal Model

  Mice

• End Point

  Body weight, Passive Avoidance Test, Acetylcholinesterase, Neural growth factor, TNF-alpha estimation, Histopathology of Brain

• Reference Drugs

  Donepzil